Ghil Schwarz

Ghil Schwarz

Auto-generated profile, based on publicly available information

Ghil Schwarz

ASST Grande Ospedale Metropolitano Niguarda

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in International Journal of Stroke
Verified
Journal Article
Closed access
GSGhil Schwarz
Ghil Schwarz
GBGargi Banerjee
Gargi Banerjee
IHIsabel C Hostettler
Isabel C Hostettler
GAGareth Ambler
Gareth Ambler
DSDavid J Seiffge
David J Seiffge
DWDavid J Werring
David J Werring
Background: Cerebral amyloid angiopathy (CAA), a common cause of intracerebral hemorrhage (ICH), is diagnosed using the Boston criteria including magnetic resonance imaging (MRI) biomarkers (cerebral microbleeds (CMBs) and cortical superficial siderosis (cSS). The simplified Edinburgh criteria include computed tomography (CT) biomarkers (subarachnoid extension (SAE) and finger-like projections (FLPs)). The underlying mechanisms and diagnostic accuracy of CT compared to MRI biomarkers of CAA are unknown. Methods: We included 140 survivors of spontaneous lobar supratentorial ICH with both acute CT and MRI. We assessed associations between MRI and CT biomarkers and the diagnostic accuracy of CT- compared to MRI-based criteria. Results: FLPs were more common in patients with strictly lobar CMB (44.7% vs 23.5%; p = 0.014) and SAE was more common in patients with cSS (61.3% vs 31.2%; p = 0.002). The high probability of the CAA category of the simplified Edinburgh criteria showed 87.2% (95% confidence interval (CI): 78.3–93.4) specificity, 29.6% (95% CI: 18.0–43.6) sensitivity, 59.3% (95% CI: 38.8–77.6) positive predictive value, and 66.4% (95%: CI 56.9–75.0) negative predictive value, 2.3 (95% CI: 1.2–4.6) positive likelihood ratio and 0.8 (95% CI 0.7–1.0) negative likelihood ratio for probable CAA (vs non-probable CAA), defined by the modified Boston criteria; the area under the receiver operating characteristic curve (AUROC) was 0.62 (95% CI: 0.54–0.71). Conclusion: In lobar ICH survivors, we found associations between putative biomarkers of parenchymal CAA (FLP and strictly lobar CMBs) and putative biomarkers of leptomeningeal CAA (SAE and cSS). In a hospital population, CT biomarkers might help rule-in probable CAA (diagnosed using the Boston criteria), but their absence is probably not as useful to rule it out, suggesting an important continued role for MRI in ICH survivors with suspected CAA.

1 May 2023 in Stroke
Verified
Journal Article
Closed access
GSGhil Schwarz
Ghil Schwarz
EAElio C. Agostoni
Elio C. Agostoni
GSGuillaume Saliou
Guillaume Saliou
SHSteven D Hajdu
Steven D Hajdu
ASAlexander Salerno
Alexander Salerno
DSDavide Strambo
Davide Strambo
Background: Little is known on the role of mismatch profile in patients undergoing early endovascular treatment (EVT). We aimed to describe pretreatment perfusion parameters and mismatch profiles in anterior circulation large vessel occlusion acute ischemic stroke undergoing EVT in the early time window and assess their association with time from stroke onset and outcomes. Methods: Retrospective single-center study, including early (2, symptomatic intracranial hemorrhage, and mortality (multivariate regression analyses [each parameter/profile entered into a separate logistic regression model, adjusted for baseline variables associated with each outcome in the univariate analysis at the P <0.1 level]). Results: Among 357 patients, unfavorable mismatch profiles ranged from 21% to 60%, depending on the criterion, and were not correlated with time from stroke onset ( P =0.490). All individual perfusion parameters and unfavorable mismatch profiles were associated with poor functional outcome: ischemic core volume adjusted odds ratio (aOR), 1.49 ([95% CI, 1.13–1.97] P =0.005); penumbral volume aOR, 0.30 ([95% CI, 0.10–0.84] P =0.022); mismatch ratio aOR, 0.67 ([95% CI, 0.50–0.90] P =0.007); EXTEND-IA aOR, 2.61 ([95% CI, 1.23–5.51] P =0.012); SWIFT PRIME aOR, 2.50 ([95% CI, 1.30–4.57] P =0.006); DEFUSE 3 aOR, 2.28 ([95% CI, 1.14–4.57] P =0.020); and DAWN aOR, 4.19 ([95% CI, 2.13–8.26] P <0.001). EXTEND-IA and DEFUSE 3 unfavorable profiles were also independently associated with symptomatic intracranial hemorrhage (aOR, 3.82 [95% CI, 1.42–10.3]; P =0.008 and aOR, 2.83 [95% CI, 1.09–7.36]; P =0.033) and death (aOR, 3.26 [95% CI, 1.33–8.02]; P =0.010 and aOR, 2.52 [95% CI, 1.10–5.82]; P =0.030). Conclusions: Pretreatment perfusion parameters and mismatch profiles in early EVT-treated patients were not correlated with time from stroke onset but were independently associated with functional outcome. Mismatch assessment in the early time window may improve EVT patient selection, independently of onset-to-treatment time.

24 February 2023 in European Journal of Neurology
Verified
Journal Article
Closed access
GSGhil Schwarz
Ghil Schwarz
SBSara Bonato
Sara Bonato
SLSilvia Lanfranconi
Silvia Lanfranconi
MMMarius Matusevicius
Marius Matusevicius
IGIsabella Ghione
Isabella Ghione
NANiaz Ahmed
Niaz Ahmed

1 March 2025 in European Stroke Journal
Verified
Journal Article
Closed access
GSGhil Schwarz
Ghil Schwarz
ARAngelo Cascio Rizzo
Angelo Cascio Rizzo
MMMarius Matusevicius
Marius Matusevicius
TMTiago Moreira
Tiago Moreira
AVAleksandras Vilionskis
Aleksandras Vilionskis
NANiaz Ahmed
Niaz Ahmed
Introduction: Endovascular treatment (EVT) improves outcomes for basilar artery occlusion (BAO) with moderate-to-severe symptoms. However, the best treatment for mild symptoms (NIHSS score 0–10 and 0–5) remains unclear. This study compared EVT ± IVT to IVT alone in BAO patients with mild symptoms. Patients and Methods: From the SITS-International Stroke Treatment Register, we included BAO patients with available baseline NIHSS score, treated by EVT, IVT, or both within 6 h of symptom onset from 2013 to 2021. Using the Doubly Robust approach (propensity score matching plus multivariable logistic regression), we analyzed efficacy (3-month mRS) and safety (SICH and 3-month death) outcomes for EVT ± IVT versus IVT alone in BAO patients with NIHSS scores 0–10 and 0–5. Results: 1426 patients were included. For NIHSS scores 0–10 (180 matched, 1:1 ratio), outcomes were similar between EVT ± IVT and IVT alone groups. For NIHSS scores 0–5 (89 matched, 1:1 ratio), EVT ± IVT was associated with worse outcomes compared to IVT alone (mRS 0–2, aOR 0.20 [95% CI 0.06–0.61]; p = 0.005; mRS 0–3, aOR 0.27 [95% CI 0.08–0.89]; p = 0.031), but safety outcomes were similar. Discussion: In early-treated BAO patients with mild symptoms, defined as NIHSS 0–10, there were no significant differences in outcomes between EVT ± IVT and IVT alone. However, for very mild symptoms, defined as NIHSS 0–5, IVT alone was associated with better outcomes compared to EVT ± IVT.Conclusion: Randomized trials are crucial to determine the optimal reperfusion therapy for BAO patients with mild symptoms.

1 March 2023 in Stroke
Verified
Journal Article
Closed access
GSGhil Schwarz
Ghil Schwarz
ARAngelo Cascio Rizzo
Angelo Cascio Rizzo
MMMarius Matusevicius
Marius Matusevicius
GGGiuditta Giussani
Giuditta Giussani
PIPaolo Invernizzi
Paolo Invernizzi
NANiaz Ahmed
Niaz Ahmed
Background: The benefit of distinguishing between disabling versus nondisabling deficit in mild acute ischemic stroke due to endovascular thrombectomy-targetable vessel occlusion (EVT-tVO; including anterior circulation large and medium-vessel occlusion) is unknown. We compared safety and efficacy of acute reperfusion treatments in disabling versus nondisabling mild EVT-tVO. Methods: From the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register, we included consecutive acute ischemic stroke patients (2015–2021) treated within 4.5 hours, with full NIHSS items availability and score ≤5, evidence of intracranial internal carotid artery, M1, A1-2, or M2-3 occlusion. After propensity score matching, we compared efficacy (3-month modified Rankin Scale score of 0–1, modified Rankin Scale score of 0–2, and early neurological improvement) and safety (nonhemorrhagic early neurological deterioration, any intracerebral or subarachnoid hemorrhage, symptomatic intracranial hemorrhage, and death at 3-month) outcomes in disabling versus nondisabling patients—adopting an available definition. Results: We included 1459 patients. Propensity score matched analysis of disabling versus nondisabling EVT-tVO (n=336 per group) found no significant differences in efficacy (modified Rankin Scale score 0–1: 67.4% versus 71.5%, P =0.336; modified Rankin Scale score 0–2: 77.1% versus 77.6%, P =0.895; early neurological improvement: 38.3% versus 44.4%, P =0.132) and safety (nonhemorrhagic early neurological deterioration: 8.5% versus 8.0%, P =0.830; any intracerebral hemorrhage or subarachnoid hemorrhage: 12.5% versus 13.3%, P =0.792; symptomatic intracranial hemorrhage: 2.6% versus 3.4%, P =0.598; and 3-month death: 9.8% versus 9.2%, P =0.844) outcomes. Conclusions: We found similar safety and efficacy outcomes after acute reperfusion treatment in disabling versus nondisabling mild EVT-tVO; our findings suggest to adopt similar acute treatment approaches in the 2 groups. Randomized data are needed to clarify the best reperfusion treatment in mild EVT-tVO.

24 March 2026 in Neurology
Verified
Journal Article
Open access
GSGhil Schwarz
Ghil Schwarz
ARAngelo Cascio Rizzo
Angelo Cascio Rizzo
GAGareth Ambler
Gareth Ambler
PWPawel Wrona
Pawel Wrona
ASAgnieszka Slowik
Agnieszka Slowik
MSMaria Sessa
Maria Sessa
Contrast-associated acute kidney injury (CA-AKI) is a potentially preventable complication after exposure to iodinated contrast media. In patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke (AIS), the incidence and clinical impact are poorly characterized, and no validated prediction tool is currently available. The aim of this study was to assess the incidence and prognostic significance of CA-AKI in EVT-treated patients with AIS and to develop and validate a predictive score. A retrospective, multicenter cohort study was conducted involving EVT-treated patients across 73 centers in 16 countries (January-December 2023). Inclusion criteria were age ≥18 years, absence of dialysis, availability of preprocedural and 48-hour postprocedural creatinine levels, and available 90-day follow-up (modified Rankin Scale [mRS] score). The primary outcome was CA-AKI, defined by KDIGO (Kidney Disease: Improving Global Outcomes criteria;creatinine increase ≥0.3 mg/dL or ≥1.5 times baseline, within 48 hours). Secondary outcomes were (1) in-hospital mortality, (2) 90-day mRS score, and (3) 90-day severe disability or death (mRS score >3). Logistic models assessing associations with outcomes accounted for within-center clustering by applying robust standard errors. CA-AKI prediction models were developed across imputed data sets using univariable selection (p < 0.20), backward elimination (p < 0.05), and coefficient-based scoring after categorization of continuous predictors, with internal validation by bootstrap to obtain optimism-adjusted estimates. Among 6,638 patients (median age 74 years; 48.7% male), CA-AKI occurred in 326 (4.9%) and was independently associated with in-hospital mortality (adjusted odds ratio [aOR] 2.269; 95% CI 1.615-3.190), higher 90-day mRS scores (adjusted common odds ratio 1.584; 95% CI 1.110-2.258), and 90-day severe disability or death (aOR 1.530; 95% CI 1.057-2.216). A preprocedural risk model including 12 routine clinical variables-sex, ethnicity, arterial hypertension, dyslipidemia, chronic kidney disease, antiplatelet therapy, NIH Stroke Scale score at admission, serum glucose, estimated glomerular filtration rate, hemoglobin, mean arterial pressure, and IV thrombolysis-demonstrated acceptable discrimination (area under the receiver operating characteristic curve 0.710 [95% CI 0.682-0.738]; precision-recall area under the curve 0.13 [95% CI 0.10-0.16]), good calibration (slope 0.870 [95% CI 0.759-0.928]), good overall performance (Brier score 0.045 [95% CI 0.042-0.049]). A second model that included EVT-related variables (e.g., contrast volume) showed similar performances. In this large, international cohort, CA-AKI occurred in approximately 1 in 20 EVT-treated patients with AIS and was independently associated with poor outcomes. A simple preprocedural risk score enables early identification of high-risk individuals and may support preventive strategies.